Omeros Corp (Omeros) is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing small-molecule and protein therapeutics. The company primarily targets large-market and orphan indications related to immunologic diseases, including complement-mediated diseases, cancers associated with immune system dysfunction, and addictive and compulsive disorders. Omeros' business portfolio includes a diverse pipeline of small-molecule and protein therapeutics. The company is advancing multiple development programs focused on diseases associated with the complement system, which is part of the body's immune response.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Omeros is advancing novel research and development programs for small-molecule and protein therapeutics to address both orphan and large-market indications. The company's current areas of focus include complement-mediated diseases, central nervous system disorders, and immuno-oncology. Omeros is targeting and exclusively controlling a broad range of previously untapped receptors and enzymes, resulting in first-in-class therapeutics designed to improve and save the lives of patients. The company is evaluating narsoplimab (OMS721) in lectin pathway-mediated diseases such as stem cell transplant-associated thrombotic microangiopathy (TA-TMA) and others. Omeros is also studying OMS906 in a number of alternative pathway-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH), complement 3 glomerulopathy (C3G), and others. Additionally, Omeros is developing OMS527, a PDE7 inhibitor, for addiction and compulsive disorders, and has a new core therapeutic platform designed for broad application throughout oncology. The company is also advancing a Targeted Complement Activation Therapy (T-CAT) platform to address drug-resistant pathogens. The R&D unit includes expertise in discovery research, preclinical development, product formulation, analytical and medicinal chemistry, manufacturing, clinical development, and regulatory and quality assurance. The company holds worldwide exclusive licenses to issued patents and pending patent applications in the U.S. and foreign markets directed to therapeutic compositions and methods, and other technologies related to its research and development programs. The pipeline of preclinical development programs includes MASP-2 small-molecule inhibitors, MASP-3 small-molecule inhibitors, OncotoX-AML, and Targeted Complement Activating Therapy (T-CAT) for multidrug-resistant organisms. The company has a major technology alliance with Novo Nordisk for the development and commercialization of zaltenibart (OMS906). In FY2025, the company spent US$81.3 million on its R&D activities, which decreased 31.9% YoY.